Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sarepta Therapeutics
Sarepta Therapeutics
Sarepta outlines final push for Duchenne gene therapy
BioPharma Dive
Mon, 10/11/21 - 09:52 pm
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Sarepta adds another gene therapy to its ever-expanding pipeline
Biopharma Dive
Wed, 08/4/21 - 10:40 pm
Sarepta Therapeutics
muscular dystrophy
Limb Girdle Muscular Dystrophy
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
Mon, 06/21/21 - 11:11 am
clinical trials
Merck
Ridgeback Biotherapeutics
COVID-19
Intellia Therapeutics
transthyretin amyloidosis
Arcus Biosciences
Gilead Sciences
lung cancer
Sanofi
GSK
vaccines
uniQure
Huntington's disease
Mirati Therapeutics
gene editing
Seres Therapeutics
ulcerative colitis
Sarepta Therapeutics
Duchenne Muscular Dystrophy
The "Rare Disease Company Coalition" Launches to Share the Unique Challenges and Promise of Rare Disease Therapy Development to Support Continued Progress and Patient Access
Yahoo/Businesswire
Thu, 05/13/21 - 12:04 pm
Rare Diseases
Rare Disease Company Coalition
drug development
drug discovery
Acceleron
Aeglea BioTherapeutics
Agios Pharmaceuticals
Alnylam
Harmony Biosciences
Orchard Therapeutics
Orphazyme
Sarepta Therapeutics
Taysha Gene Therapies
Ultragenyx
Sarepta's second-gen Duchenne drug shows signs of topping its first
BioPharma Dive
Mon, 05/3/21 - 10:54 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
gene therapy
The next 2 months in biotech and pharma will be busy. Here's what to watch.
BioPharma Dive
Tue, 04/20/21 - 11:16 pm
Biogen
aducanumab
FDA
Vertex Pharmaceuticals
Sarepta Therapeutics
JNJ
AstraZeneca
vaccines
COVID-19
Is Sarepta Therapeutics Worthy of Redemption?
Motley Fool
Fri, 04/2/21 - 10:52 am
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
With new results, Sarepta's 2nd gene therapy holds steady
BioPharma Dive
Sun, 03/21/21 - 11:46 pm
Sarepta Therapeutics
gene therapy
limb-girdle muscular dystrophy
FDA Approves Third Sarepta Treatment For Duchenne Muscular Dystrophy
BioSpace
Sun, 02/28/21 - 10:15 pm
Sarepta Therapeutics
Amondys 45
Duchenne Muscular Dystrophy
FDA
Go or no go? Oncology decisions ahead for the FDA
EP Vantage
Wed, 01/27/21 - 11:55 am
FDA
cancer
oncology
Bristol-Myers Squibb
TG Therapeutics
Mallinckrodt
Sanofi
Regeneron
Sarepta Therapeutics
GSK
Oncopeptide
JPM21: Biogen faces make-or-break year, Vertex mulls deals and Sarepta pitches a silver lining
BioPharma Dive
Mon, 01/11/21 - 07:06 pm
JPMHC 2021
Biogen
Vertex Pharmaceuticals
Sarepta Therapeutics
Sarepta's DMD gene therapy fails phase 2 motor function test, sinking stock
Fierce Biotech
Fri, 01/8/21 - 09:30 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
SRP-9001
Pfizer beats Sarepta to the start of first late-stage Duchenne gene therapy trial
BioPharma Dive
Thu, 01/7/21 - 11:36 am
Pfizer
Sarepta Therapeutics
clinical trials
Duchenne Muscular Dystrophy
gene therapy
Sarepta shares first results on next-generation Duchenne drug
BioPharma Dive
Tue, 12/8/20 - 11:13 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-5051
Exondys 51
FDA gene therapy holdups suggest closer scrutiny by agency
BioPharma Dive
Fri, 11/6/20 - 10:07 am
FDA
gene therapy
Sarepta Therapeutics
Voyager Therapeutics
Iovance
Bluebird Bio
Sarepta partner Lysogene reports patient death in AAVance clinical trial
The Fly
Thu, 10/15/20 - 11:01 am
Sarepta Therapeutics
Lysogene
patient deaths
clinical trials
gene therapy
New data bolsters Sarepta gene therapies for two deadly muscle diseases
Biopharma Dive
Mon, 09/28/20 - 10:45 am
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
Limb Girdle Muscular Dystrophy
SRP-9001
SRP-9003
Sarepta faces another gene therapy hiccup as Regenxbio sues over Jim Wilson's patent
Endpoints
Thu, 09/17/20 - 10:40 am
Sarepta Therapeutics
gene therapy
Regenxbio
Duchenne Muscular Dystrophy
Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay
Fierce Biotech
Fri, 09/11/20 - 10:55 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Marketwatch
Thu, 09/10/20 - 10:21 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »